A. Balil

992 total citations
12 papers, 711 citations indexed

About

A. Balil is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Balil has authored 12 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Cancer Research and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Balil's work include Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and HER2/EGFR in Cancer Research (4 papers). A. Balil is often cited by papers focused on Breast Cancer Treatment Studies (8 papers), Cancer Treatment and Pharmacology (8 papers) and HER2/EGFR in Cancer Research (4 papers). A. Balil collaborates with scholars based in Spain, Chile and United States. A. Balil's co-authors include Miguel Martín, Carlos Jara, Antonio Casado, Encarna Adrover, Antonieta Salud, Emilio Alba, Agustí Barnadas, Àngels Arcusa, Bo Nordenskjöld and Margarita Amenedo and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Lancet Oncology.

In The Last Decade

A. Balil

12 papers receiving 696 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Balil Spain	9	423	267	211	176	79	12	711
Marry H. Nieuwenhuis Netherlands	13	388 0.9×	105 0.4×	353 1.7×	175 1.0×	312 3.9×	15	942
Anna Felisiak-Gołąbek Poland	14	200 0.5×	90 0.3×	206 1.0×	96 0.5×	90 1.1×	20	544
Souzan Sanati United States	16	227 0.5×	241 0.9×	211 1.0×	160 0.9×	35 0.4×	30	611
Reiner Caspari Germany	17	767 1.8×	283 1.1×	273 1.3×	341 1.9×	136 1.7×	37	1.6k
Nikolaos Givalos Greece	12	321 0.8×	95 0.4×	92 0.4×	274 1.6×	26 0.3×	13	678
Paola Sala Italy	22	846 2.0×	243 0.9×	401 1.9×	242 1.4×	345 4.4×	45	1.5k
R. Bracci Italy	16	337 0.8×	173 0.6×	350 1.7×	184 1.0×	25 0.3×	42	768
Isamu Hayashi Japan	12	173 0.4×	119 0.4×	212 1.0×	128 0.7×	14 0.2×	20	507
Ilkka Heiskanen Finland	14	217 0.5×	110 0.4×	153 0.7×	225 1.3×	94 1.2×	31	671
Emma J. Groen Netherlands	9	243 0.6×	205 0.8×	65 0.3×	83 0.5×	36 0.5×	15	485

Countries citing papers authored by A. Balil

Since Specialization

Citations

This map shows the geographic impact of A. Balil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Balil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Balil more than expected).

Fields of papers citing papers by A. Balil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Balil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Balil. The network helps show where A. Balil may publish in the future.

Co-authorship network of co-authors of A. Balil

This figure shows the co-authorship network connecting the top 25 collaborators of A. Balil. A scholar is included among the top collaborators of A. Balil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Balil. A. Balil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Francis, Prudence A., John Crown, Angelo Di Leo, et al.. (2008). Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. JNCI Journal of the National Cancer Institute. 100(2). 121–133. 111 indexed citations

Pestalozzi, Bernhard C., Prudence A. Francis, Emmanuel Quinaux, et al.. (2008). Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. Annals of Oncology. 19(11). 1837–1841. 13 indexed citations

Martín, Miguel, Amparo Ruı́z, A. Balil, et al.. (2007). Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. The Lancet Oncology. 8(3). 219–225. 139 indexed citations

Haba-Rodríguez, Juan de la, Enrique Aranda, Antonio Llombart‐Cussac, et al.. (2007). Time-to-progression in breast cancer: A stratification model for clinical trials. The Breast. 17(3). 239–244. 2 indexed citations

Muñoz-Mateu, Montserrat, Miguel Martín, A. Balil, et al.. (2006). Phase III study of gemcitabine plus vinorelbine (VG) versus vinorelbine (V) in patients (pts) with metastatic breast cancer (MBC) previously treated with anthracyclines (A) and taxanes (T). Final results of GEICAM 2000–04 study. Journal of Clinical Oncology. 24(18_suppl). 575–575. 5 indexed citations

Crown, John, Prudence A. Francis, Angelo Di Leo, et al.. (2006). Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2–98 Trial at 5 years median follow-up (MFU). Journal of Clinical Oncology. 24(18_suppl). LBA519–LBA519. 21 indexed citations

Aparicio, Jorge, J.R. Germà, Xavier García del Muro, et al.. (2005). Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. Journal of Clinical Oncology. 23(34). 8717–8723. 134 indexed citations

Alba, Emilio, Miguel Martín, Manuel Ramos, et al.. (2004). Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. Journal of Clinical Oncology. 22(13). 2587–2593. 97 indexed citations

Martín, Miguel, Carlos Jara, Agustí Barnadas, et al.. (2003). Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Annals of Oncology. 15(1). 79–87. 62 indexed citations

10.

Martín, Miguel, José L. García-Puche, Antonio Casado, et al.. (2003). High-dose DICEP chemotherapy versus observation in metastatic breast cancer patients with monotopic disease responding to induction chemotherapy with paclitaxel plus epirubicin. Final results of a phase III GEICAM trial. 5(3). 148–155. 1 indexed citations

11.

Salud, Antonieta, et al.. (2002). [Unilateral exophthalmos secondary to orbital metastasis as initial manifestation of breast cancer].. PubMed. 19(3). 159–159. 38 indexed citations

12.

Cirera, Luis, A. Balil, E. Batiste-Alentorn, et al.. (1999). Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer. Journal of Clinical Oncology. 17(12). 3810–3815. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact